This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 2VB
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Provention Bio, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$22.78 |
| 52 Week Low | US$3.23 |
| Beta | 2.46 |
| 1 Month Change | -0.60% |
| 3 Month Change | 174.81% |
| 1 Year Change | 391.47% |
| 3 Year Change | 111.76% |
| 5 Year Change | n/a |
| Change since IPO | 495.04% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 2VB | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | -4.2% | 1.5% | -0.5% |
| 1Y | 391.5% | -27.9% | 2.5% |
Rentabilidad vs. Industria: 2VB exceeded the German Pharmaceuticals industry which returned -0.9% over the past year.
Rentabilidad vs. Mercado: 2VB exceeded the German Market which returned -3.3% over the past year.
Volatilidad de los precios
| 2VB volatility | |
|---|---|
| 2VB Average Weekly Movement | 65.7% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 2VB's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 2VB's weekly volatility has increased from 34% to 66% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 174 | Ashleigh Palmer | www.proventionbio.com |
Resumen de fundamentos de Provention Bio, Inc.
| Estadísticas fundamentales de 2VB | |
|---|---|
| Capitalización bursátil | €2.15b |
| Beneficios(TTM) | -€103.03m |
| Ingresos (TTM) | €11.70m |
183.6x
Ratio precio-ventas (PS)-20.8x
Ratio precio-beneficio (PE)¿Está 2VB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2VB | |
|---|---|
| Ingresos | US$12.90m |
| Coste de los ingresos | US$76.32m |
| Beneficio bruto | -US$63.42m |
| Otros gastos | US$50.14m |
| Beneficios | -US$113.56m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.20 |
| Margen bruto | -491.83% |
| Margen de beneficio neto | -880.69% |
| Ratio deuda/patrimonio | 19.3% |
¿Cómo se ha desempeñado 2VB a largo plazo?
Ver rendimiento histórico y comparativa